Predictive Oncology Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.2772
- Today's High:
- $0.333
- Open Price:
- $0.28
- 52W Low:
- $0.21
- 52W High:
- $0.985
- Prev. Close:
- $0.277
- Volume:
- 1176989
Company Statistics
- Market Cap.:
- $22.52 million
- Book Value:
- 0.276
- Revenue TTM:
- $1.51 million
- Operating Margin TTM:
- -1014.16%
- Gross Profit TTM:
- $1.00 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -27.46%
- Return on Equity TTM:
- -82.98%
Company Profile
Predictive Oncology Inc had its IPO on 2018-01-29 under the ticker symbol POAI.
The company operates in the Healthcare sector and Medical Instruments & Supplies industry. Predictive Oncology Inc has a staff strength of 31 employees.
Stock update
Shares of Predictive Oncology Inc opened at $0.28 at the start of the last trading session i.e. 2023-03-31.
The stocks traded within a range of $0.28 - $0.33, and closed at $0.33.
This is a +17.98% increase from the previous day's closing price.
A total volume of 1,176,989 shares were traded at the close of the day’s session.
In the last one week, shares of Predictive Oncology Inc have increased by +9.66%.
Predictive Oncology Inc's Key Ratios
Predictive Oncology Inc has a market cap of $22.52 million, indicating a price to book ratio of 1.0917 and a price to sales ratio of 19.5901.
In the last 12-months Predictive Oncology Inc’s revenue was $1.51 million with a gross profit of $1.00 million and an EBITDA of $-13954640. The EBITDA ratio measures Predictive Oncology Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Predictive Oncology Inc’s operating margin was -1014.16% while its return on assets stood at -27.46% with a return of equity of -82.98%.
In Q4, Predictive Oncology Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 23.7%.
Predictive Oncology Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.36 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Predictive Oncology Inc’s profitability.
Predictive Oncology Inc stock is trading at a EV to sales ratio of 4.4097 and a EV to EBITDA ratio of -0.5133. Its price to sales ratio in the trailing 12-months stood at 19.5901.
Predictive Oncology Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $25.73 million
- Total Liabilities
- $3.88 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $276189
- Dividend Payout Ratio
- 0%
Predictive Oncology Inc ended 2023 with $25.73 million in total assets and $0 in total liabilities. Its intangible assets were valued at $25.73 million while shareholder equity stood at $21.77 million.
Predictive Oncology Inc ended 2023 with $0 in deferred long-term liabilities, $3.88 million in other current liabilities, 787627.00 in common stock, $-153777916.00 in retained earnings and $0.00 in goodwill. Its cash balance stood at $22.07 million and cash and short-term investments were $22.07 million. The company’s total short-term debt was $94,237 while long-term debt stood at $0.
Predictive Oncology Inc’s total current assets stands at $23.36 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $331196.00 compared to accounts payable of $943452.00 and inventory worth $430493.00.
In 2023, Predictive Oncology Inc's operating cash flow was $0 while its capital expenditure stood at $276189.
Comparatively, Predictive Oncology Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $0.33
- 52-Week High
- $0.985
- 52-Week Low
- $0.21
- Analyst Target Price
- $5
Predictive Oncology Inc stock is currently trading at $0.33 per share. It touched a 52-week high of $0.985 and a 52-week low of $0.985. Analysts tracking the stock have a 12-month average target price of $5.
Its 50-day moving average was $0.41 and 200-day moving average was $0.39 The short ratio stood at 0.58 indicating a short percent outstanding of 0%.
Around 608.4% of the company’s stock are held by insiders while 583.5% are held by institutions.
Frequently Asked Questions About Predictive Oncology Inc
Similar Industry Stocks (Medical Instruments & Supplies)
Most Active
Top Gainers
Top Losers
About
Predictive Oncology Inc., a knowledge-driven company, focuses on developing optimal cancer therapies using artificial intelligence (AI) in the United States. The company operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers AI-driven predictive models of tumor drug response to enhance clinical outcomes for patients; and patient-centric drug discovery using active learning asset technology. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.